Motivation: The computational evaluation of candidate genes for hereditary disorders is a non-trivial task. Several excellent methods for disease-gene prediction have been developed in the past 2 decades, exploiting widely differing data sources to infer disease-relevant functional relationships between candidate genes and disorders. We have shown recently that spatially mapped, i.e. 3D, gene expression data from the mouse brain can be successfully used to prioritize candidate genes for human Mendelian disorders of the central nervous system. Results: We improved our previous work 2-fold: (i) we demonstrate that condition-independent transcription factor binding affinities of the candidate genes' promoters are relevant for disease-gene prediction and can be integrated with our previous approach to significantly enhance its predictive power; and (ii) we define a novel similarity measure-termed Relative Intensity Overlap-for both 3D gene expression patterns and binding affinity profiles that better exploits their disease-relevant information content. Finally, we present novel disease-gene predictions for eight loci associated with different syndromes of unknown molecular basis that are characterized by mental retardation. Contact: r.piro@dkfz.de or
INTRODUCTION
Although experimental methodologies for the identification of disease-causing mutations have significantly improved-in particular by the recently introduced next-generation sequencing techniques-computational approaches to an in silico evaluation of candidate genes remain an important aid for the identification of genes involved in human hereditary disorders (Kann, 2010; Piro et al., 2011; Piro and Di Cunto, 2012) . A large variety of computational methods have been developed for this purpose, exploiting various data sources ranging from MEDLINE abstracts, functional gene annotation, protein-protein interactions and high-throughput gene expression data to intrinsic gene or protein properties (such as coding sequence length, number of introns, conservation and so forth). For more information on available disease-gene prediction tools and methods, we refer to some recent reviews (Kann, 2010; Piro and Di Cunto, 2012) .
To a large extent, cellular homeostasis depends on coordinated gene expression, both in space and time. Gene expression determines where and when the molecular function of a gene product is exerted. For this reason, gene expression patterns have been successfully exploited by several computational disease-gene prediction methods (Kann, 2010; Piro and Di Cunto, 2012) .
In our previous work (Piro et al., 2010) , we have shown that the high-resolution 3D gene expression patterns provided by the Allen Institute's Mouse Brain Atlas (MBA) (Lein et al., 2007) can be used to successfully prioritize not only candidate genes for mouse phenotypes but also for human Mendelian disorders of the central nervous system (CNS). Briefly, we prioritized the candidate genes from a mapped 'orphan' locus of a disease phenotype with unknown molecular basis by comparing their 3D gene expression patterns to those of a set of 'reference genes', known to be involved in similar disease phenotypes.
The condition and sample dependency of gene expression profiles constitutes a desired feature for the prediction of functional relationships between genes. A complementary view, and hence additional clues to gene functions, may instead be provided by condition-independent regulatory information, obtained from promoter analysis (Werner, 2003) . Classically, position frequency matrices (PFMs) or their associated position weight matrices (PWMs) that describe transcription factor (TF) binding sites are used to scan promoters for short, often degenerate, regulatory elements. In many cases, genome-wide PWM scans require stringent criteria to limit the false-discovery rate and to yield an acceptable specificity. This can lead to reduced sensitivity and likely misses low-affinity binding sites (Hannenhalli, 2008) , which have been shown to be abundant and functional in vivo (Tanay, 2006) .
An alternative approach builds on the notion of an overall likelihood that a promoter is bound by a given TF, without requiring the identification of one or more well-defined regulatory elements (Foat et al., 2006; Molineris et al., 2011; Ward and Bussemaker, 2008) , thus better reflecting the thermodynamic nature of TF binding (Segal et al., 2008) . For this purpose, a total binding affinity (TBA) for the TF's PFM can be calculated over the entire promoter, taking into account the collective contribution of (potential) high-and low-affinity binding sites, without strictly drawing a line between binding and non-binding sites. In a recent study, we showed TBA to be predictive of TFbinding events, as revealed by ChIP/chip and ChIP/seq experiments (Molineris et al., 2011) .
Here, we introduce the notion of TF binding co-affinity of a pair of genes that we compute from the genes' TBA profiles composed of their binding affinities for a core set of TFs. We show that these co-affinities can decipher the disease relevance of candidate genes for human hereditary disorders and further improve the predictive power by developing a new similarity measure termed Relative Intensity Overlap (RIO). We combine this approach with the prioritization based on spatially mapped, i.e. 3D, gene expression, applying it to several disorders of unknown molecular basis characterized by mental retardation (MR).
METHODS

Disease phenotypes and gene-disease associations
Information on human Mendelian disease phenotypes was obtained from the Online Mendelian Inheritance in Man (OMIM) database (Amberger et al., 2009) on August 15, 2011, limited to those that contain the term 'central nervous system' in their clinical synopsis section and have at least one mapped disease locus. Note that this selection criterion does not exclude other organs and tissues from being affected, i.e. symptoms need not be limited to the CNS. A total of 867 OMIM phenotype entries with known molecular basis (OMIM symbol: #) were downloaded. Associated disease-related genes were determined by merging information from the OMIM Morbidmap and Entrez Gene (Sayers et al., 2012) (mim2gene), yielding 948 CNS-related gene-phenotype (g-p) pairs. Additionally, we obtained all phenotype entries for various syndromes with an unknown molecular basis (OMIM symbol: %) that contain the term 'mental retardation' (MR) in their title field and have been mapped to a disease locus containing a set of candidate genes.
As our aim was to predict the most likely candidates for mapped 'orphan' loci from OMIM phenotype entries with so far unknown molecular basis, in which no genes are known to be involved, we used diseaseassociated genes from similar phenotype entries as reference genes for the prediction procedure described later in the text. For this purpose, we measured the pairwise similarity of OMIM phenotypes using MimMiner, essentially as described by van Driel et al. (2006) . MimMiner scores are normalized and range from 0 (unrelated) to 1 (highly related or identical). Instead of the minimum score of 0.4 proposed by van Driel et al. to define phenotype similarity, we applied a more stringent threshold of 0.5 to focus on more relevant reference genes.
For the ex novo candidate gene prioritizations that we present here, we restricted our analysis to eight representative orphan disease loci for both X-linked and autosomal MR that had at least two reference genes from similar phenotypes and at least 20 candidate genes for which both gene expression and affinity data were available (see later in the text).
3D gene expression data
3D gene expression profiles for the MBA (Lein et al., 2007) were downloaded on February 2, 2011 using the application programming interface provided by the Allen Institute's website at http://mouse.brain-map.org/. Only sagittal image series with antisense probes for genes with defined Entrez gene IDs were considered. In case of multiple image series per gene, only the most recent series was used. The downloaded expression patterns provide expression levels for the entire brain, smoothed over evenly spaced voxels (cubes) with a side length of 200 m.
As we applied the mouse expression data for prioritizing human disease genes, we mapped expression profiles from the mouse brain to human Entrez gene IDs using unambiguous mappings from NCBI's HomoloGene (build 65) (Sayers et al., 2012) , yielding 14 590 human Entrez gene IDs with an associated expression pattern from the mouse brain. From these, we excluded 68 genes that had no corresponding TBA profiles (see later in the text).
3D expression patterns from the MBA consist only of non-negative values (!0) that we normalized as follows: for each profile, we first sorted all positive expression levels (40) in increasing order and then set the 95th percentile to a value of 0.95 (to avoid taking outliers into account for normalization). All other expression values were scaled linearly by the same factor. Expression levels that exceeded 1 after scaling were interpreted as potential outliers and limited to equal 1.
Brain region-specific gene expression
To evaluate the performance of different correlation measures in clustering spatial expression profiles, we used sets of genes that exhibit regionspecific expression in the mouse brain. Of the top 100 genes for each of 12 brain regions, defined by Lein et al. (2007) , we retained only those that could be unambiguously mapped to human genes (see earlier in the text), obtaining between 77 and 92 (on average 84) genes per region.
We then used a rank-based procedure to construct ranked co-expression groups (RCGs; Miozzi et al., 2008) for all 14 522 genes, each being composed of the gene that defines the RCG plus the k genes with the most correlated 3D gene expression profiles (where correlation is defined by one of the tested similarity measures). Varying k from 1 to 100, we scanned the RCGs for gene pairs from the 12 brain region-specific gene sets.
Total binding affinity and co-affinity
As described in our recent study on the evolution of promoter-TF affinity, for each human transcription start site, we consider the region spanning 1500 bp upstream to 500 bp downstream as promoter, but the approach is robust with respect to the choice of promoter size (Molineris et al., 2011) .
Following Foat et al. (2006) , we define the TBA a rw of a promoter r for a transcription factor, represented by its position frequency matrix (PFM) w, as:
where L is the length of the promoter, l is the length of the PFM, r i is the nucleotide at position i of the promoter and r 0 i is the nucleotide at the same position on the opposite strand.
The probability Pðw j , r iþj Þ to observe a given nucleotide r iþj at promoter position i þ j also at position j of the PFM w is computed as the PFM's frequency count of the nucleotide at w j , divided by the total frequency count for all four nucleotides at w j . In the case of a frequency count of zero, we add a pseudocount of 1. Pðw j , r iþj Þ is corrected for the background probability Pðb, r iþj Þ of r iþj , computed as the nucleotide frequency for the whole intergenic part of the human genome.
For genes with multiple promoters r (i.e. multiple transcription start sites), we set the gene's TBA a gw for a given PFM w (i.e. a given transcription factor or transcription factor family) to the maximum value obtained for its individual promoters r k , i.e.
where nðgÞ is the number of promoters r of gene g. This is biologically reasonable because a single promoter of the gene is in principle sufficient to drive its expression (although the promoter may allow to produce only some of the possible isoforms of the gene).
As affinities from different PFMs are in most cases not directly comparable [because of widely differing lengths l and nucleotide frequencies Pðw j Þ;we finally apply a z-transformation to the TBA scores a gw , such that each gene g's TBA is represented by the direction and number of standard deviations it differs from the mean TBA a w for the given PFM w. We computed TBAs of 130 non-redundant vertebrate PFMs deposited in the Jaspar Core database (Bryne et al., 2008) for 37 231 human promoters defined by transcription start sites from RefSeq (Pruitt et al., 2007) . We could map the RefSeq IDs to 22 120 Entrez gene IDs (using only unambiguous mappings). Consequently, each gene g can be described by a TBA profileã g ¼ ða gw1 , a gw2 , . . . , a gw130 Þ composed of its (z-transformed) affinities for the transcription factors represented by the PFMs [Equations (1) and (2)]. However, we limit the evaluation presented here to those 14 522 genes, i.e. TBA profiles, for which MBA profiles are also available (see earlier in the text).
Similar to the co-expression between two genes that can be estimated from their gene expression profiles, we define the co-affinity of two genes as the similarity of their TBA profiles (with different possible measures of similarity). To this notion of co-affinity, we can apply the same candidate gene prioritization and leave-one-out cross validation (LOOCV) procedures defined for gene expression (see later in the text).
Relative intensity overlap
We define the RIO of two 3D gene expression profiles a and b (that can be thought of as 3D images) as follows:
where I a xyz and I b xyz are intensities, i.e. expression levels, at voxel xyz for genes a and b, respectively, and sums P xyz are calculated over all voxels.
Interpretation: The RIO measures the overlap of two (normalized) 3D gene expression profiles by multiplying them with each other and summing the contributions of the single voxels to an overall score. This score is then normalized through division by the maximum possible overlap that would be obtained if both profiles had for each voxel the higher expression level of the two. This way, a maximum contribution to the score can be obtained for I Analogously, we define the RIO of two TBA profiles m and n as in Equation (3), using as intensities the (z-transformed) TBAs a mw and a nw and summing over the PFMs w instead of summing over voxels.
Note that RIOs can range from 0 to 1 if the intensities are non-negative quantities (as is the case for the MBA expression data) or from À1 to 1 if the intensities can include negative values (as is the case for the z-transformed TBAs) because in the latter case, discordant intensities can yield negative contributions (if, e.g. a mw 4 0 and a nw 5 0).
Candidate gene prioritization
For both MBA and TBA profiles, we use the candidate gene prioritization method, outlined in Figure 1 , that we defined in our previous study for 3D gene expression profiles (Piro et al., 2010) .
Briefly, for each reference gene r 2 R p , selected for a given OMIM disease phenotype p (via MimMiner; see earlier in the text), all other genes are ranked according to the similarity of their MBA or TBA profiles, respectively, to obtain one genome-wide, ranked co-expression or co-affinity list for each r (columns in Fig. 1 ). For this purpose, profile similarity can be defined in various ways, for example, by the Pearson correlation coefficient [PCC; used in Piro et al. (2010) for the MBA data] or the RIO that we propose here (see earlier in the text).
The given set of candidate genes C p (e.g. candidates from an orphan disease locus) has now to be prioritized, i.e. ranked, according to their likelihood of being involved in p. We apply the following procedure: the rank/position kðc, rÞ of each candidate gene c 2 C p within each of the ranked profile similarity lists (columns) of the reference genes r is determined, and a relative rank kðc, rÞ=k max computed, where k max is the total number of genes in the ranked lists. Subsequently, each candidate gene is assigned an overall score s c , determined as the product of its relative ranks within the reference genes' co-expression or co-affinity lists,
and candidates are sorted, i.e. prioritized, according to their increasing overall score, thus giving precedence to lower scores (as lower scores indicate better rankings in the single profile similarity lists and, therefore, a higher probability of being functionally related to the reference genes). For more details, see Piro et al. (2010) .
Leave-one-out cross validation
To demonstrate the validity of our approach-including the new similarity measure and the prediction based on affinity profiles-we performed large-scale LOOCVs for all known gene-disease phenotype associations (g-p pairs) regarding CNS-related Mendelian disorders from OMIM (see earlier in the text). For each g-p pair, we removed all gene-disease associations of p and constructed an 'artificial locus' containing the diseaserelated gene g itself plus the N closest genes on both sides of the chromosome (for N ¼ 50, N ¼ 100, N ¼ 200 and N ¼ 400), hence, simulating an orphan locus of at most 2N þ 1 genes (or less for g close to a chromosome terminal) linked to an OMIM phenotype of unknown molecular basis. Then, we prioritized the candidates from the artificial loci and verified the absolute rank (R g ) and relative rank R rel g (¼rank R g divided by the number of candidates) of the true disease-related gene g within the prioritized candidate list.
The analysis was limited to gene-phenotype pairs whose corresponding artificial loci contain at least 50 'effective' candidate genes for which both MBA and TBA profiles are available-one of which was required to be g itself-as only these can be evaluated and thus prioritized. For a lower number of effective candidate genes, an undesired bias would tend to automatically place the true phenotype-causing gene g in high ranks R g . See Table 1 for the number of gene-phenotype pairs that could be evaluated.
Integration of candidate rankings
To obtain overall rankings for a given set of candidate genes, we first compute distinct candidate rankings for the MBA-based and the TBAbased approach, respectively, as illustrated in Figure 1 . For each candidate gene c, we determine its (predicted) ranks R M c and R T c from the two ranked candidate lists (M ¼ MBA, T ¼ TBA). Using an adaptation of the generalized noisy-OR gate defined by Dı´ez (1993) , we compute the conditional probability that c 's true rank R Ã c is 1 (i.e. c is the true disease gene) as
i.e. the probability that c is the true disease gene conditionally on having been ranked at position R M c for the MBA, multiplied by the probability that it is the true disease gene given that it has been ranked at position R T c for the TBA. We determine the probability PðR LOOCV results obtained with the PCC and the RIO as similarity measure (Sim.) for (a) TBA-based predictions and (b) MBA-based predictions. (c) Results obtained for the integrated approach (TBA þ MBA). N represents the size of the artificial loci having a maximum of 2N þ 1 genes. The average numbers of effective candidates C p with both TBA and MBA profiles and the numbers of evaluated g-p pairs are shown. The observed (Obs.) and expected (E.) numbers of g-p pairs, for which the true phenotype-causing gene g ranks first, among the top three, among the top 10 and within the best 10% of the prioritized list, are reported along with the corresponding P-values (one-tailed Fisher's exact test). Grey background highlights the results obtained with our previous method (upper box) and the new integrated approach (lower box). Bold face font highlights the improvements for this comparison (improvement for all results but one; none worsened).
a Results for which the RIO outperforms the PCC. Fig. 1 . Schematic representation of the disease-gene prioritization procedure, exemplified with two of the hypothetical candidate genes c i and four reference genes r i associated to a phenotype p. The procedure is first applied individually to MBA profiles and TBA profiles, and the resulting prioritized candidate lists are integrated into an overall ranking. The locus containing the candidate genes C p , the disease phenotype p and the expression and affinity profiles are considered as given [adapted from Piro et al. (2010) ]
corresponding to the fraction of evaluated gene-phenotype pairs for which the true disease gene g ranked R D c , like the candidate gene c. To prevent probabilities from becoming nil, we add a pseudocount of one.
Finally, we determine an integrated candidate gene list by prioritizing the candidates c according to their decreasing probability [Equation (5) 
RESULTS
Promoter-TF binding affinities are predictive
We performed LOOCVs over all known CNS-related gene-disease associations to verify whether TBA profiles can actually aid in prioritizing candidate genes from known disease loci. At the same time, we asked whether the frequently used PCC or our new similarity measure, the RIO, would better suit this task. For this purpose, we constructed artificial candidate loci of various sizes around each known disease gene and compared the candidates' TBA profiles with those of related reference genes, using either PCC or RIO as similarity measure.
As demonstrated in Table 1a , TBA profiles are indeed predictive and can be used to successfully prioritize candidate genes. Furthermore, our new similarity measure RIO outperforms the PCC for all locus sizes and for all evaluated categories of diseasegene rankings (first, top three, top 10 and best 10%). The number of disease genes correctly being ranked first, for example, is increased by 47-333% depending on the locus size. Likewise, RIO outperforms both the Spearman rank correlation (SRC) and the cosine-similarity (COS), as shown in Supplementary Table S1a. Thus, for comparing binding affinity profiles, we chose to use our new similarity measure.
RIO for predictions based on 3D gene expression
The measurement of profile similarity is of major interest also when applying 3D gene expression patterns to evaluate which candidate genes are more likely to be functionally associated with a given disorder. We asked whether RIO outperforms PCCused both in our previous work (Piro et al., 2010) and by the Allen Institute (Lein et al., 2007) -in clustering spatial expression profiles and predicting likely candidates for CNS-related disorders. In addition, we compared the results with those obtained for SRC and COS.
To evaluate the performance in clustering spatial expression profiles, we constructed RCGs (Miozzi et al., 2008) of varying sizes k þ 1 (k ¼ 1 to 100) for all genes and all four profile similarity measures, and we counted the number of pairs of genes within these RCGs known to be specifically expressed in the same brain region (see Section 2). Figure 2 shows that for the MBA, RIO can consistently better recover region-specific relationships between gene expression patterns. For RCGs consisting only of each gene plus it's genome-wide most correlated gene (k ¼ 1), for example, RIO identifies 233 gene pairs specifically expressed in the same brain region, whereas PCC, COS and SRC identify only 199, 180 and 153, respectively. For evaluating RIO's impact on predicting likely candidates for CNS-related disorders, we performed additional LOOCVs. As shown in Table 1b , RIO performs comparably with PCC with respect to true disease-associated genes that are ranked among the first three, first 10 or the best 10% of the candidate genes from artificial loci. Furthermore, when considering disease-genes that are ranked first among the set of candidates-the ones that would preferably be evaluated by geneticists on the search for causes of hereditary disease-RIO clearly outperforms PCC (increase of 12-44%). In this regard, it also compares favourably with both SRC and COS, as shown in Supplementary Table S1b. Therefore, in the following sections, we used our new similarity measure also for this type of gene expression data.
However, the performance improvement of the RIO depends on a proper normalization of the 3D gene expression data. For the LOOCV results for raw MBA profiles along with a discussion, see the Supplementary Information (Supplementary Table  S2 and accompanying text).
Complementarity of MBA and TBA
As the MBA gene expression data and the TBAs regard two different species (mouse and human) and consider two largely different aspects of gene expression (dynamic, tissue-and location-specific expression levels versus a static, condition-independent predisposition for binding events), we reasoned that a joint application of both could be beneficial for the purpose of prioritizing candidate genes for hereditary disorders.
For the RIO and the smallest artificial loci (N ¼ 50), for example, the disease-associated gene g ranked first or second for 45 g-p pairs with the MBA-based and for 42 g-p pairs with the TBA-based approach, respectively, but there was no overlap at all between these correct predictions (see Supplementary Table S3 ). Overall, median Spearman correlation coefficients of the leave-one-out rankings obtained for MBA and TBA were close to zero, ranging from 0.031 (for N ¼ 50) to 0.044 (for N ¼ 400). This indicates that successful predictions of the MBA-based approach are usually not obtained through the TBA-based approach and vice versa, providing a strong rationale for an integration of the two approaches. Therefore, we integrated the results obtained for the two individual prioritizations using an adaptation of the generalized noisy-OR gate (see Section 2). We found that their complementarity considerably increases the predictive power with respect to our previous work (Piro et al., 2010) . This becomes clear when comparing the results for MBA-based predictions with PCC (grey box in Table 1b )-reflecting the same method that we used for our previous study-with those for the new combined approach (Table 1c ). Indeed, for the different locus sizes and evaluation categories, the number of recovered disease genes increased by up to 226% (for N ¼ 400 and ranking among the top 10). Bo¨rnigen et al. (2012) have recently evaluated eight commonly used candidate gene prioritization methods and obtained realistic performance estimates for ex novo predictions by applying the tools to novel gene-disease associations within a few days of their publication. They obtained areas under the receiver operating characteristic curves (AUCs) of 0.56-0.86.
Comparison to other prioritization methods
In comparison, for our unbiased LOOCV over the largest artificial loci (N ¼ 400), containing the most candidates, we obtained an AUC of 0.81 (see Supplementary Fig. S1 ). Only two of the tools tested by Bo¨rnigen et al. (2012) , GeneDistiller (Seelow et al., 2008) and Endeavour (Aerts et al., 2006) obtained slightly higher AUCs (0.86 and 0.83, respectively) . Hence, the performance of our approach is generally in line with the most efficient approaches commonly being used.
Novel predictions for mental retardation
Given the positive outcome of the large-scale LOOCV that simulates the application of our method to OMIM phenotypes of unknown molecular basis (OMIM symbol: %), we applied the procedure to the eight partly overlapping orphan loci listed in Table 2 that are involved in various syndromes (both autosomal and X-linked) of which MR is an important clinical feature.
DISCUSSION
Regulatory information from PWM scans has previously been used as an additional information source in a number of candidate gene prioritization methods (Kann, 2010; Piro and Di Cunto, 2012) . However, because of the stringent criteria that are often necessary to decide whether a specific DNA segment is a binding site, leading to reduced sensitivity and a likely disregard of possibly functional low-affinity binding sites (Hannenhalli, 2008) , it is unlikely that information from PWM scans alone would be suitable for disease-gene discovery. Likewise, the benefit of more comprehensive TBA profiles is not immediately clear and has previously not been explored on a large scale.
Although gene function can often be inferred from primary coding sequences, deciphering functional properties exclusively from non-coding sequences is much more difficult (Carroll, 2005) . For one, co-affinity is static and condition-independent; hence, it does not directly translate into the co-expression of, say, two genes in brain tissues. In contrast to gene expression data, the concept of binding affinity does not implicitly integrate information on different types of regulatory control (such as the methylation state of promoters, nucleosome positioning and the post-transcriptional downregulation by microRNAs). Instead, co-affinities, being calculated from promoter sequences only, are limited to the direct binding of TFs to promoters.
Second, even a successful binding event must not necessarily alter transcription rates if, for example, required co-factors are lacking in a specific tissue. Indeed, Gao et al. (2004) suggest that as much as 42% of TF binding may be non-functional in yeast.
Finally, binding affinity profiles constitute a description of a cis-regulatory sequence, in this case, the promoter, involved in the regulatory control of a gene (Molineris et al., 2011) . But given the incompleteness of the TBA profiles we considered (composed of a core set of 130 PWMs; see Section 2) or, more general, the incompleteness of our knowledge regarding functional TF binding, a successful application of this kind of information to disease-gene prediction was not necessarily guaranteed (for a more detailed discussion, see Supplementary Text S1).
Nonetheless, in this study, we could show that regulatory information alone, in the form of TBA-based co-affinities, can indeed prioritize candidate genes for hereditary disorders. Further improvements of the predictive power were obtained by the application of a new similarity measure, RIO, and by integration with our previous approach based on 3D gene expression patterns (Piro et al., 2010) . We exploited the new integrated approach to identify promising candidates for several MR syndromes (Table 2) .
Strikingly, among the best candidates for most of the orphan loci, we found genes that have been reported to be implicated in one or more other MR-related syndromes (Table 2 and  Supplementary Table S5) . Notably, several of these MR genes obtained high ranks, although they were not included in our original set of known gene-disease associations (and, hence, in our set of possible reference genes). For example, synaptophysin (SYP) is involved in MR, X-linked 96 (OMIM ID #300802) (Tarpey et al., 2009) , whose phenotype entry is brief and does not contain the term 'central nervous system' in its clinical synopsis. Nonetheless, we found the gene among the top 3% candidates for the largest orphan locus, cubitus valgus with MR and unusual facies (OMIM %300471), underlining that our method is indeed capable to identify promising candidate genes that are not yet known to be linked to MR. Likewise, ZMYM3, our top candidate for the Prieto X-linked MR syndrome (OMIM %309610), is not associated to any CNS-related phenotype entry in OMIM, although a chromosomal translocation (X;13) involving ZMYM3 is associated with X-linked MR (van der Maarel et al., 1996) .
Additionally to known MR genes, some of our top ranking candidates have already been suggested as possibly being involved in MR syndromes or have been implicated in, or proposed for, other neurological diseases (including neurodegenerative disorders like Alzheimer's disease; Table 2 and  Supplementary Table S5) .
For space reasons, here, we discuss only the top candidates for alopecia/MR syndrome 1 (APMR1; %203650), originally described by Baraitser et al. (1983) .
Genetic syndromes characterized by alopecia (hair loss) and severe MR are rare disorders of largely unknown molecular basis. In 2006, by studying a large consanguineous family from Pakistan, John et al. (2006) mapped the APMR1 locus to the 5.4 Mb region on chromosome 3 located between markers D3S1232 and D3S2436. Of the candidates at this locus, they screened for mutations in coding exons only the transcription factor ETV5, but no abnormalities were found (John et al., 2006) . Interestingly, we found ETV5 as the second best candidate. However, although it is in principle possible that mutations affecting its regulatory regions may be responsible for the phenotype, this seems unlikely on the basis of the available functional information. Indeed, ETV5 loss of function has been shown to affect the maintenance of spermatogonial stem cells (Chen et al., 2005) and kidney development (Lu et al., 2009) , whereas ETV5 overexpression has been linked to ovarian cancer (Llaurado´et al., 2012) .
The only top 10 candidate that has been linked to an MR-related disorder is MCCC1, mutations of which are known to be responsible for 3-methylcrotonyl-CoA carboxylase 1 deficiency (Baumgartner et al., 2001; Gallardo et al., 2001) , which is characterized by multiple clinical features, one of which can be MR (Murayama et al., 1997; Steen et al., 1999) . Alopecia, however, is generally not a feature of the disease, although a possible association has been reported in a single case (Leonard et al., 1981) .
However, as a particular strength of the predictive method that we present here is an extrapolation of functional relationships from reference genes to candidate genes that-relying on gene expression and sequence information alone-do not require any known functional annotation, less obvious candidates could nonetheless be associated with the disorder.
The first candidate, CLCN2, encodes a voltage-gated chloride channel, previously implicated in idiopathic generalized epilepsies (Haug et al., 2003) . DCUN1D1, ranking third, is another interesting candidate because a polymorphism has been identified as a risk factor in frontotemporal lobar degeneration (Villa et al., 2009) . Also DVL3, ranking forth, is of particular interest because the protein it encodes interacts with Shank, which is involved in several neuronal disorders including MR (Saupe et al., 2011) . Table S6) , although adiponectin, the protein it encodes, is thought to be expressed specifically in adipose tissue (Hu et al., 1996) . Nonetheless, recent research indicates that the secreted protein influences the proliferation of adult hippocampal neural stem/progenitor cells that express adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2) (Zhang et al., 2011) , and adiponectin deficiency could also negatively impact brain microcirculation (Vachharajani et al., 2012) . Moreover, a low-protein level and a mutation of the corresponding gene were found in a patient affected by Werner syndrome (Hashimoto et al., 2007) , which is characterized, among other features, by prominent hair loss.
We think that these examples show well how the predictions obtained by our approach could support geneticists to dissect the molecular basis of many ill-defined human disorders.
